EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient-reported Outcomes after Standard and Dose-escalated Prostate Stereotactic Body Radiotherapy

D Sugahara, H Yamashita, H Ueno, T Hayashi, Y Kasuga, A Yasui, H Mizumoto, K Nakatani, S Sawayanagi, Y Nozawa, M Ogita

Clinical Oncology · 2026-11 · 59 · 104337

DOI: 10.1016/j.clon.2026.104337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Oncology, 2026-11. Verfasst von D Sugahara und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiosurgery, Patient Reported Outcome Measures. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Dose escalation may improve tumor control in prostate stereotactic body radiotherapy (SBRT), but its impact on patient-reported outcomes (PROs) remains unclear. We evaluated urinary and bowel PROs after prostate SBRT, focusing on the impact of dose escalation. MATERIALS AND METHODS: This single-institution retrospective cohort study included consecutive patients treated with five-fraction prostate SBRT between 2016 and 2024. The primary outcomes were Expanded Prostate Cancer Index Composite (EPIC) urinary irritative/obstructive (EPIC-UIR) and bowel (EPIC-B) scores. Patients with at least one EPIC-UIR or EPIC-B assessment within 36 months after treatment were included. Prescribed dose varied over time according to institutional clinical practice. Patients were categorized into a lower-dose group (≤40 Gy) and a higher-dose group (>40 Gy). Linear mixed-effects models were used to evaluate longitudinal trajectories. Clinically meaningful deterioration was assessed using minimal clinically important difference (MCID)-based analyses in the acute (1- and 3-month timepoints) and late (6- to 36-month timepoints) phases. RESULT: Among 940 patients treated with SBRT, 872 patients constituted the subjects of the PRO analysis, including 672 in the lower-dose group and 200 in the higher-dose group. In both groups, urinary and bowel scores showed acute decline followed by early recovery. Compared with the lower-dose group, the higher-dose group showed less favorable late urinary outcomes in both longitudinal analyses (P < .001) and MCID-based analyses, with late urinary worsening observed in 68% versus 80% of patients (P = .007). CONCLUSION: Dose escalation in prostate SBRT may involve a trade-off with late urinary PROs, highlighting the need for careful consideration of urinary organs at risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsRadiosurgeryPatient Reported Outcome MeasuresHumansMaleRetrospective StudiesAgedRadiotherapy DosageAged, 80 and overMiddle Aged

Stichwörter der Autor:innen

Dose escalationpatient-reported outcomesprostatic neoplasmsquality of lifestereotactic body radiotherapyurinary toxicity

Autor:innen und Institutionen

  • Department of Radiology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
  • Department of Radiology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. Electronic address: yamachan07291973@yahoo.co.jp.

Zitieren

APA

Sugahara, D., Yamashita, H., Ueno, H., Hayashi, T., Kasuga, Y., Yasui, A., Mizumoto, H., Nakatani, K., Sawayanagi, S., Nozawa, Y., & Ogita, M. (2026). Patient-reported Outcomes after Standard and Dose-escalated Prostate Stereotactic Body Radiotherapy. Clinical Oncology, 59, 104337. https://doi.org/10.1016/j.clon.2026.104337

Vancouver

Sugahara D, Yamashita H, Ueno H, Hayashi T, Kasuga Y, Yasui A, et al. Patient-reported Outcomes after Standard and Dose-escalated Prostate Stereotactic Body Radiotherapy. Clinical Oncology. 2026;59:104337. doi:10.1016/j.clon.2026.104337

BibTeX
@article{Sugahara2026,
  author = {Sugahara, D and Yamashita, H and Ueno, H and Hayashi, T and Kasuga, Y and Yasui, A and Mizumoto, H and Nakatani, K and Sawayanagi, S and Nozawa, Y and Ogita, M},
  title = {Patient-reported Outcomes after Standard and Dose-escalated Prostate Stereotactic Body Radiotherapy},
  journal = {Clinical Oncology},
  year = {2026},
  volume = {59},
  pages = {104337},
  doi = {10.1016/j.clon.2026.104337}
}
Kostenlos starten →